HC Wainwright Reduces Earnings Estimates for Urogen Pharma

Urogen Pharma (NASDAQ:URGN) – Equities researchers at HC Wainwright cut their Q3 2025 earnings per share estimates for shares of Urogen Pharma in a research note issued to investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.73) per share for the quarter, down from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($1.18) EPS.

Several other brokerages have also recently weighed in on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Urogen Pharma in a report on Tuesday, August 5th. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research report on Friday, June 13th. Guggenheim reissued a “buy” rating and issued a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Finally, Scotiabank reissued an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $31.43.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN opened at $20.08 on Thursday. The company’s 50-day moving average price is $15.21 and its two-hundred day moving average price is $11.59. Urogen Pharma has a one year low of $3.42 and a one year high of $21.01. The stock has a market capitalization of $928.90 million, a PE ratio of -6.05 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. The business had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million.

Insider Buying and Selling

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company’s stock, valued at $794,156.88. This trade represents a 15.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the transaction, the insider directly owned 148,229 shares of the company’s stock, valued at approximately $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,833 shares of company stock worth $457,467 over the last three months. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Alliancebernstein L.P. lifted its position in Urogen Pharma by 751.5% during the fourth quarter. Alliancebernstein L.P. now owns 199,259 shares of the company’s stock worth $2,122,000 after acquiring an additional 175,859 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Urogen Pharma by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 461,902 shares of the company’s stock valued at $4,919,000 after purchasing an additional 6,265 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Urogen Pharma by 2.7% during the fourth quarter. Wells Fargo & Company MN now owns 221,540 shares of the company’s stock worth $2,359,000 after purchasing an additional 5,801 shares during the period. Legal & General Group Plc lifted its holdings in Urogen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after purchasing an additional 3,920 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $1,472,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.